Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Emerging Nosocomial Pathogen Isolated from Prosthetic Joint Infections

By LabMedica International staff writers
Posted on 10 Jan 2017
Further knowledge about the clinical and microbiological characteristics of prosthetic joint infections (PJIs) caused by different coagulase-negative staphylococci (CoNS) may facilitate interpretation of microbiological findings and improve treatment algorithms.

The implementations of new methods, such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) or real-time broad-range polymerase chain reaction (PCR), has simplified the identification of CoNS to the species level.

A team of Swedish scientists working with those at the Linköping University (Sweden) performed retrospective cohort study included three centres and 21 patients with significant growth of Staphylococcus capitis during revision surgery for PJI between 2005 and 2014. More...
Clinical data were extracted and further microbiological characterisation of the S. capitis isolates was performed.

CoNS isolated in equal to or greater than two perioperative tissue samples obtained from revision surgery for hip or knee arthroplasties due to PJI were included for further analysis. If there were not at least two CoNS isolates with similar colony morphology and antimicrobial resistance pattern, the patient was excluded. MALDI-TOF MS was performed for species identification using a Microflex LT (Bruker Daltonik GmbH, Bremen, Germany).

To discriminate between the subspecies of S. capitis, urease activity and maltose fermentation tests were performed, using both tube test and API-ID32 STAPH (bioMérieux, Marcy l’Etoile, France). Standard antibiotic susceptibility testing by the disc diffusion test was also performed. The bioMérieux DiversiLab semi-automatic repetitive sequence-based PCR microbial genotyping system was used to detect the genomic fingerprints of each S. capitis isolate.

Ten patients experienced monomicrobial infections and among patients available for evaluation, 86% of chronic infections and 70% of early post-interventional infections achieved clinical cure; 90 % of monomicrobial infections remained infection-free. Multidrug-resistant S. capitis was detected in 28.6 % of isolates, methicillin resistance in 38.1 % and fluoroquinolone resistance in 14.3 %, but no isolates were rifampin-resistant. Heterogeneous glycopeptide-intermediate resistance was detected in 38.1 % and biofilm-forming ability was common.

The authors concluded that Staphylococcus capitis has the potential to cause PJIs, with infection most likely being contracted during surgery or in the early postoperative period. As S. capitis might be an emerging nosocomial pathogen, surveillance of the prevalence of PJIs caused by S. capitis could be recommended. The study was published in the January 2017 issue of the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:
Linköping University
Bruker Daltonik
bioMérieux

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.